WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has been awarded a grant of $267,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant, which was awarded as part of MJFF’s Novel Approaches to Drug Discovery for Parkinson’s Disease 2009 initiative, is designed to fund research to explore nNOS inhibitors as a potential novel treatment paradigm for Parkinson’s disease.
